Testing effectiveness (Phase 2)Active Not RecruitingNCT03698994
What this trial is testing
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Who this might be right for
Advanced Malignant Solid NeoplasmRecurrent Ependymal TumorRecurrent Ewing Sarcoma+33 more
National Cancer Institute (NCI) 20